Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint
Open Access
- 30 September 2010
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 9 (5), 332-338
- https://doi.org/10.1016/j.jcf.2010.05.004
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Clinical Use of Ibuprofen Is Associated with Slower FEV1 Decline in Children with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2007
- A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic FibrosisThe New England Journal of Medicine, 2006
- Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and CanadaPediatric Pulmonology, 1999
- Intermittent Administration of Inhaled Tobramycin in Patients with Cystic FibrosisThe New England Journal of Medicine, 1999
- Spirometric Reference Values from a Sample of the General U.S. PopulationAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Longitudinal analysis of pulmonary function decline in patients with cystic fibrosisThe Journal of Pediatrics, 1997
- Identifying Treatments That Halt Progression of Pulmonary Disease in Cystic FibrosisPediatric Research, 1997
- Effect of High-Dose Ibuprofen in Patients with Cystic FibrosisThe New England Journal of Medicine, 1995
- Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic FibrosisThe New England Journal of Medicine, 1994
- Pulmonary function between 6 and 18 years of agePediatric Pulmonology, 1993